 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- |||| ADX-324 / ADARx
Enrollment open: STOP-HAE: A Phase 3 Study of ADX-324 in HAE (clinicaltrials.gov) - Jul 8, 2025
P3, N=90, Recruiting, Sponsor: ADARx Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting
- |||||||| ADX-324 / ADARx
New P3 trial: STOP-HAE: A Phase 3 Study of ADX-324 in HAE (clinicaltrials.gov) - May 7, 2025
P3, N=90, Not yet recruiting, Sponsor: ADARx Pharmaceuticals, Inc.
- || ADX-324 / ADARx
Trial primary completion date: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients (clinicaltrials.gov) - Nov 14, 2024
P1, N=53, Recruiting, Sponsor: ADARx Pharmaceuticals, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jan 2025 --> Jul 2025
- || ADX-324 / ADARx
Trial completion date, Trial primary completion date: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients (clinicaltrials.gov) - Mar 29, 2024
P1, N=53, Recruiting, Sponsor: ADARx Pharmaceuticals, Inc.
Trial primary completion date: Jan 2025 --> Jul 2025 Trial completion date: Nov 2024 --> Dec 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
- ADX-324 / ADARx
HAE Prophylaxis by Targeting Prekallikrein With siRNA- Phase 1 Interim Safety Outcomes and Prekallikrein Levels (Monitor 12) - Sep 14, 2023 - Abstract #ACAAI2023ACAAI_876;
P1
Conclusion The interim outcomes provide preliminary evidence that ADX-324 is safe and significantly decreases PKK levels for at least 3 months. This should translate to effective prevention of HAE attacks with convenient long intervals between doses.
- | ADX-324 / ADARx
New P1 trial: Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients (clinicaltrials.gov) - Jan 20, 2023
P1, N=53, Recruiting, Sponsor: ADARx Pharmaceuticals, Inc.